[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610415":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":98,"collaborators":11,"id":100,"slug":11,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":11,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":116,"conditions":117,"keywords":11,"overallStatus":120,"whyStopped":11,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"EG 427","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who received EG110A in a clinical study, regardless of dose","EXPERIMENTAL",null,[13,14,15],"Other: Urodynamics","Drug: EG110A","Other: Patient-reported Outcome",[17,22,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"OTHER","Urodynamics","standardized local evaluation of urodynamic parameters",[9],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","EG110A","Patients already treated with EG110A",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Patient-reported Outcome","assessment of participant's perception of the level of impairment in functioning and well-being associated with NDO symptoms",[9],[32],{"name":33,"affiliation":5,"role":34},"Cornelia Haag-Molkenteller, MD","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Sandrine Zourbas, Ph.D.","CONTACT","33 (0)625622802","szourbas@eg427.com",{"name":33,"role":38,"phone":11,"phoneExt":11,"email":42},"Cornelia@eg427.com",[44,59,72,85],{"facility":45,"status":11,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Rancho Los Amigos National Rehabilitation Center","Downey","California","90242","United States",{"type":51,"coordinates":52},"Point",[53,54],-118.13257,33.94001,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":11,"phoneExt":11,"email":11},"Evgeniy Kreydin, MD",{"facility":60,"status":11,"city":61,"state":62,"zip":63,"country":49,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"University of Michigan Rogel Cancer Center","Ann Arbor","Michigan","48109",{"type":51,"coordinates":65},[66,67],-83.74088,42.27756,{"lat":67,"lon":66},[70],{"name":71,"role":38,"phone":11,"phoneExt":11,"email":11},"John Stoffel, MD",{"facility":73,"status":11,"city":74,"state":75,"zip":76,"country":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Sidney Kimmel Medical College","Philadelphia","Pennsylvania","19107",{"type":51,"coordinates":78},[79,80],-75.16362,39.95238,{"lat":80,"lon":79},[83],{"name":84,"role":38,"phone":11,"phoneExt":11,"email":11},"Patrick Shenot, MD",{"facility":86,"status":11,"city":87,"state":88,"zip":89,"country":49,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"UTHealth Houston \u002F TIRR Memorial Hermann","Houston","Texas","77030",{"type":51,"coordinates":91},[92,93],-95.36327,29.76328,{"lat":93,"lon":92},[96],{"name":97,"role":38,"phone":11,"phoneExt":11,"email":11},"Argyrios Stampas, MD",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610415",false,"NCT07227285","Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy","Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F","Inclusion Criteria:\n\n\\- All participants who received at least one dose\u002Finjection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study.\n\nExclusion Criteria:\n\n* Participant plans to participate in another investigational gene therapy study\n* Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator","ALL","18 Years","75 Years",{"count":110,"type":111},16,"ESTIMATED","INTERVENTIONAL",[114,115],"PHASE1","PHASE2","The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose\u002Finjection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.",[118,119],"Urinary Bladder, Overactive","Spinal Cord Injury","NOT_YET_RECRUITING","2025-11-10",{"date":123,"type":124},"2025-11-12","ACTUAL",{"date":126,"type":111},"2026-04",{"date":128,"type":111},"2031-04",{"name":5,"class":6},4]